Insight Molecular Diagnostics
IMDX
30 hedge funds and large institutions have $15.5M invested in Insight Molecular Diagnostics in 2016 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 4 increasing their positions, 9 reducing their positions, and 5 closing their positions.
2,846% more capital inflows, than outflows
Capital inflows: $6.26M | Capital outflows: $212K
4.5% more ownership
Funds ownership: 6.23% → 10.73% (+4.5%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
12% less funds holding
Funds holding: 34 → 30 (-4)
56% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 9
80% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Broadwood Capital
New York
|
+$6.21M |
| 2 |
Destination Wealth Management
Walnut Creek,
California
|
+$36.2K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$11.7K |
| 4 |
BlackRock Investment Management
Wilmington,
Delaware
|
+$1.05K |
| 5 |
Citigroup
New York
|
+$161 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
-$105K |
| 2 |
MHP
Manatuck Hill Partners
Westport,
Connecticut
|
-$47.2K |
| 3 |
Paloma Partners
Greenwich,
Connecticut
|
-$42K |
| 4 |
Tower Research Capital (TRC)
New York
|
-$5.57K |
| 5 |
Morgan Stanley
New York
|
-$3.8K |
IMDX Hedge Fund Activity: Q3 2016 in Review
30 of the 3,759 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q3 2016, worth a combined $15.5M — up 175% from $5.64M a quarter earlier.
Sellers outnumbered buyers: 5 funds closed out of IMDX and 1 opened new positions — a net loss of 4 holders — while 9 trimmed existing stakes and 4 added.
The largest buyer was Broadwood Capital, adding an estimated $6.21M. The largest seller was Goldman Sachs, exiting entirely with an estimated $105K sold.
- 30 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q3 2016, down from 34 in Q2 2016.
- Funds reported $15.5M of Insight Molecular Diagnostics stock for Q3 2016, up 175% quarter-over-quarter.
- 1 fund opened new Insight Molecular Diagnostics positions in Q3 2016 and 5 closed out, a net change of -4 holders.
- The largest Insight Molecular Diagnostics buyer in Q3 2016 was Broadwood Capital, an estimated $6.21M added.
- The largest Insight Molecular Diagnostics seller in Q3 2016 was Goldman Sachs, an estimated $105K sold.
Based on aggregated 13F filings for Q3 2016.